Serum Selenium and Zinc Levels in Non-alcoholic Fatty Liver Disease Patients
NCT04834063 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80
Last updated 2021-11-02
Summary
Non-alcoholic fatty liver disease (NAFLD) includes a wide range of disorders that consist of simple fatty infiltration, steatohepatitis (NASH), and end-stage liver disease (cirrhosis). NAFLD is the most common cause of chronic liver disease worldwide and increases the risk of end-stage liver disease and hepatocellular carcinoma (HCC) . While risk factors such as obesity, diabetes, and a sedentary lifestyle may increase the risk of NAFLD, studies have shown that environmental exposures may further contribute to the pathogenesis of NAFLD. Although the pathogenic role of macronutrients is well established in both NAFLD and obesity, the contribution of micronutrients to NAFLD pathogenesis has garnered less attention than with obesity.
Selenium is an essential element in many biological functions and is an important component of human nutrition. Exposure to selenium can be found in nature, such as rocks and sediment, air, soil, fuel oil, drinking water and nutritional supplementation. It is a major component of many enzymes such as glutathione peroxidase and plays an important role in anti-oxidation, DNA synthesis, reproduction, muscle function, and thyroid metabolism. Selenium concentrations have been studied in many diseases and organ systems including the liver. However, the exact relationship between selenium in patients with NAFLD is unclear.
Selenium is an essential element in many biological functions and is an important component of human nutrition. It is a major component of many enzymes such as glutathione peroxidase and plays an important role in anti-oxidation, DNA synthesis, reproduction, muscle function, and thyroid metabolism. Selenium concentrations have been studied in many diseases and organ systems including the liver. However, the exact relationship between selenium in patients with NAFLD is unclear.
Despite data suggesting mineral deficiencies in NAFLD patients, most data do not support insufficient mineral consumption as a possible mechanism for these deficiencies, except in the case of zinc deficiency. Zinc is the second most prevalent trace element in the body. It is integrally involved in the normal life cycle and has many important regulatory, catalytic, and defensive functions. Zinc deficiency occurs in many types of liver disease, especially more advanced/decompensated disease.
Conditions
- NAFLD
Interventions
- DIAGNOSTIC_TEST
-
Serum Zinc a level
Diagnostic test
- DIAGNOSTIC_TEST
-
serum selenium level
Diagnostic test
- DIAGNOSTIC_TEST
-
Fibroscan measurement
Diagnostic test
Sponsors & Collaborators
-
Sohag University
lead OTHER
Principal Investigators
-
Radwa Farag, MD · Sohag University
-
Yasser Amin, MD · Sohag University
-
Haitham Attia, MD · Sohag University
-
Ahmed Abdallah, MD · Sohag University
Eligibility
- Min Age
- 20 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-03-15
- Primary Completion
- 2021-09-05
- Completion
- 2021-09-25
Countries
- Egypt
Study Locations
More Related Trials
-
The Impact of Deferasirox on Non-Alcoholic-Steatohepatitis
NCT01278056 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Different Doses of ZED1227 vs. Placebo in NAFLD
NCT05305599 ·Status: COMPLETED ·Phase: PHASE2
-
Nutritional Intervention IN Nash NON-ALCOHOLIC (NAFLD).
NCT05946330 ·Status: UNKNOWN ·Phase: NA
-
Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis
NCT03863574 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis
NCT05357352 ·Status: COMPLETED
-
Ambulatory Liver Fat Monitoring in Patients With Non-alcoholic Fatty Liver Disease
NCT05754385 ·Status: COMPLETED ·Phase: NA
-
Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis
NCT03061721 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients
NCT06863376 ·Status: RECRUITING ·Phase: PHASE2
-
The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus
NCT06117137 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease
NCT06739486 ·Status: NOT_YET_RECRUITING
-
Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment
NCT01987310 ·Status: WITHDRAWN ·Phase: NA
-
A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver
NCT03357380 ·Status: COMPLETED ·Phase: PHASE1
-
Influence of Diabetic Control on the Degree of Liver Fibrosis Assessed by Non-invasive Scores in Patients Followed in Diabetology
NCT05605821 ·Status: NOT_YET_RECRUITING
-
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis
NCT05573204 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Quantifying Hepatic Mitochondrial Fluxes in Humans
NCT05305287 ·Status: RECRUITING ·Phase: PHASE4
-
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
NCT04880187 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis
NCT06302049 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)
NCT02605616 ·Status: TERMINATED ·Phase: PHASE2
-
NASH and Type 2 Diabetes: Role of the Receptor Activator of Nuclear Factor-κB (RANK) and Its Ligand (RANKL)
NCT03968354 ·Status: UNKNOWN
-
A Study on Diagnosis and Treatment of End Stage Liver Disease Complicated With Infection (SESLDIR Study)
NCT03363451 ·Status: UNKNOWN
-
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
NCT04483947 ·Status: COMPLETED ·Phase: PHASE1
-
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease
NCT04330326 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Efficacy and Safety of Roflumilast in Patients with NASH
NCT06677788 ·Status: COMPLETED ·Phase: PHASE2
-
6-week Safety and PD Study in Adults With NAFLD
NCT03256526 ·Status: COMPLETED ·Phase: PHASE2
-
Selenoprotein P and Non-alcoholic Fatty Liver Disease
NCT01257685 ·Status: COMPLETED